What is the share price of Nectar Lifesciences Ltd (NECLIFE) today?
The share price of NECLIFE as on 18th September 2026 is ₹10.98. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nectar Lifesciences Ltd (NECLIFE) share?
The past returns of Nectar Lifesciences Ltd (NECLIFE) share are- Past 1 week: -7.81%
- Past 1 month: -2.83%
- Past 3 months: -5.59%
- Past 6 months: -2.05%
- Past 1 year: -32.68%
- Past 3 years: -57.11%
- Past 5 years: -62.27%
What are the peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE)?
The peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE) include:What is the market cap of Nectar Lifesciences Ltd (NECLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nectar Lifesciences Ltd (NECLIFE) is ₹213.30 Cr as of 18th September 2026.What is the 52 week high and low of Nectar Lifesciences Ltd (NECLIFE) share?
The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is ₹22.40 and the 52-week low is ₹9.30.What is the PE and PB ratio of Nectar Lifesciences Ltd (NECLIFE) stock?
The P/E (price-to-earnings) ratio of Nectar Lifesciences Ltd (NECLIFE) is -0.73. The P/B (price-to-book) ratio is 0.37.Which sector does Nectar Lifesciences Ltd (NECLIFE) belong to?
Nectar Lifesciences Ltd (NECLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nectar Lifesciences Ltd (NECLIFE) shares?
You can directly buy Nectar Lifesciences Ltd (NECLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nectar Lifesciences Ltd
NECLIFE Share Price
NSE₹10.980.18% (-0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NECLIFE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
NECLIFE Performance & Key Metrics
NECLIFE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -0.87 | 0.37 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
NECLIFE Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NECLIFE Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
NECLIFE Forecast
NECLIFE Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NECLIFE
NECLIFE
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NECLIFE Income Statement
NECLIFE Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 442.84 | 359.85 | 12.25 | 8.08 | 0.18 | 5.56 | 0.74 | 35.46 | 7.58 | 3.68 | ||||||||||
Operating & Other expenses | 392.87 | 319.50 | 6.32 | 0.05 | 130.03 | 68.63 | 176.47 | 1.92 | 89.24 | 27.71 | ||||||||||
EBITDA | 49.97 | 40.35 | 5.93 | 8.03 | -129.85 | -63.07 | -175.73 | 33.54 | -81.66 | -24.03 | ||||||||||
| Depreciation/Amortization | 14.70 | 15.46 | 0.45 | 0.07 | 0.30 | 0.53 | 0.11 | 0.06 | 0.08 | 0.11 | ||||||||||
| PBIT | 35.27 | 24.89 | 5.48 | 7.96 | -130.15 | -63.60 | -175.84 | 33.48 | -81.74 | -24.14 | ||||||||||
| Interest & Other Items | 24.16 | 19.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.22 | 5.90 | 0.16 | ||||||||||
| PBT | 11.11 | 4.91 | 5.48 | 7.96 | -130.15 | -63.60 | -175.84 | 3.26 | -87.64 | -24.30 | ||||||||||
| Taxes & Other Items | 10.52 | 1.95 | -0.12 | 0.12 | -0.06 | -0.37 | 0.16 | -11.02 | -19.72 | -8.90 | ||||||||||
| Net Income | 0.59 | 2.96 | 5.60 | 7.84 | -130.09 | -63.23 | -176.00 | 14.28 | -67.92 | -15.40 | ||||||||||
| EPS | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.38 | -0.79 |
NECLIFE Company Updates
NECLIFE Stock Peers
NECLIFE Past Performance & Peer Comparison
NECLIFE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nectar Lifesciences Ltd | -0.73 | 0.37 | — |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
NECLIFE Stock Price Comparison
Compare NECLIFE with any stock or ETFCompare NECLIFE with any stock or ETF
NECLIFE
NECLIFE Holdings
NECLIFE Shareholdings
NECLIFE Promoter Holdings Trend
NECLIFE Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 6.93%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NECLIFE Institutional Holdings Trend
NECLIFE Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.10%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NECLIFE Shareholding Pattern
NECLIFE Shareholding Pattern
NECLIFE Shareholding History
NECLIFE Shareholding History
Foreign Institutions
Mutual Funds Invested in NECLIFE
Mutual Funds Invested in NECLIFE
No mutual funds holding trends are available
Top 1 Mutual Funds holding Nectar Lifesciences Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0008% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 127/130 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NECLIFE stock
smallcases containing NECLIFE stock
Looks like this stock is not in any smallcase yet.
NECLIFE Events
NECLIFE Events
NECLIFE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NECLIFE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NECLIFE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NECLIFE has not given any dividends in last 5 years
NECLIFE Upcoming Dividends
NECLIFE Upcoming Dividends
No upcoming dividends are available
NECLIFE Past Dividends
NECLIFE Past Dividends
Cash Dividend
Ex DateEx DateSep 11, 2020
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 11, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 19, 2018
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2018
Cash Dividend
Ex DateEx DateSep 20, 2017
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 20, 2017
Cash Dividend
Ex DateEx DateSep 22, 2016
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2016
NECLIFE Stock News & Opinions
NECLIFE Stock News & Opinions
Articles & Videos
Corporate
Corporate
Nectar Lifesciences will relocate its corporate office to Chandigarh, effective September 15, 2026Nectar Lifesciences Limited informed the National Stock Exchange of India Limited and BSE Limited that its board of directors approved a change in the company's corporate office from Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002 to "Godrej Eternia," West Wing (Tower A), Plot No. 70, Industrial Area, Phase -1, Chandigarh, 160 002, effective September 15, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Nectar Lifesciences closes member register September 12-18, 2026, for its AGMNectar Lifesciences Ltd. will close its register of members and share transfer books from September 12, 2026, to September 18, 2026, for its 31st Annual General Meeting to be held on September 18, 2026, the company said in a filing with the National Stock Exchange of India Limited and BSE Limited. The cut-off date to determine eligibility for remote e-voting is September 11, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Nectar Lifesciences schedules board meeting to review quarterly financial resultsNectar Lifesciences Ltd. will hold a board meeting on Friday, August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, according to a regulatory filing.
1 month agoCapital Market - Live
Earnings
Earnings
Nectar Lifescience reports consolidated net loss of Rs 67.92 crore in the March 2026 quarterNet Loss of Nectar Lifescience reported to Rs 67.92 crore in the quarter ended March 2026 as against net loss of Rs 130.09 crore during the previous quarter ended March 2025. There were no Sales reported in the quarter ended March 2026 and during the previous quarter ended March 2025. For the full year,net loss reported to Rs 292.89 crore in the year ended March 2026 as against net loss of Rs 113.68 crore during the previous year ended March 2025. There were no Sales reported in the year ended March 2026 as against Rs 21.32 crore during the previous year ended March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Nectar Lifescience to discuss resultsNectar Lifescience will hold a meeting of the Board of Directors of the Company on 30 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Nectar Lifescience consolidated net profit rises 82.02% in the December 2025 quarterNet profit of Nectar Lifescience rose 82.02% to Rs 14.27 crore in the quarter ended December 2025 as against Rs 7.84 crore during the previous quarter ended December 2024. There were no Sales reported in the quarter ended December 2025 and during the previous quarter ended December 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Nectar Lifescience announces board meeting dateNectar Lifescience will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Nectar Lifescience to conduct board meetingNectar Lifescience will hold a meeting of the Board of Directors of the Company on 3 December 2025.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Earnings
Nectar Lifescience reports consolidated net loss of Rs 176.01 crore in the September 2025 quarterNet loss of Nectar Lifescience reported to Rs 176.01 crore in the quarter ended September 2025 as against net profit of Rs 5.60 crore during the previous quarter ended September 2024. Sales declined 12.74% to Rs 5.00 crore in the quarter ended September 2025 as against Rs 5.73 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales5.005.73 -13 OPM %-6.60-10.30 - PBDT-0.300.10 PL PBT-0.50-0.35 -43 NP-176.015.60 PL Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Nectar Lifescience announces board meeting dateNectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -64.05%, vs industry avg of 11.76%
Over the last 5 years, market share decreased from 0.53% to 0%